Molecular Partners AG (MOLN)
MOLNNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$2.86
+0.1614 (+5.98%) today
Closed, Nov 17, 4:00 PM ET
- Market cap
- $103.91m
- P/E
- –
- EPS, last 4 quarters
- $-1.68
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.63 to $5.36
- Average volume
- –
- Previous close
- $2.70
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $11.00, +284.6% from here
Earnings
next estimate $-0.4400Next report
Dec 2025
-7.9%
Mar 2026
-18.4%
Jun 2026
+2.2%
Sep 2026
+17.4%
estimate reported, and the surprise
Financials
| Quarter | Mar 2021 |
|---|---|
| Revenue | $1.04m |
| Gross profit | $1.04m |
| Operating income | -$19.69m |
| Net income | -$17.59m |
News
8 latest- After Plunging 18.3% in 4 Weeks, Here's Why the Trend Might Reverse for Molecular Partners AG Sponsored ADR (MOLN)Zacks · Nov 4, 2026
- Molecular Partners AG Announces Strategic Shift to Radiopharmaceuticals and Intends to Reduce Workforce by No More Than 55 PositionsFintel · Oct 29, 2026
- Molecular Partners Reports H1 2026 Results, Advances DLL3 Radiotherapy MP0712 RTTNews · Aug 25, 2026
- Molecular Partners Advances Phase 2 Study Of MP0317 In Cholangiocarcinoma; Stock Up RTTNews · Jul 16, 2026
- Molecular Partners Advanced Phase 2 Study Of MP0317 In Cholangiocarcinoma; Stock Up RTTNews · Jul 16, 2026
- Molecular Partners To Advance MP0726 For First Human Imaging In H2,2026; Provides MP0712 Update RTTNews · Jul 6, 2026
- Will Petrobras Pull Off Q4 Earnings Beat on Strong Production?Zacks · Mar 4, 2026
- HC Wainwright & Co. Initiates Coverage of Molecular Partners AG - Depositary Receipt (MOLN) with Buy RecommendationFintel · Jan 27, 2026
The company
Molecular Partners AG (SIX, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of medicines known as DARPin therapeutics for cancer patients underserved by existing treatment modalities. Molecular Partners focuses on the development of targeted radiotherapeutics, leveraging the unique properties of DARPin miniproteins as isotope-agnostic vector. The Company's lead medicine MP0712, targeting DLL3 and armed with 212Pb, advances in a US multicenter Phase 1/2a study for patients with small cell lung cancer and other neuroendocrine cancers (NCT07278479). Molecular Partners has established partnerships with industry leaders and academic centers covering the full value chain of radiotherapeutics. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- molecularpartners.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.